First Tracks Biotherapeutics is trading 5.21% down now at $37.51 as September 10, 2026 markets sell off following hotter-than-expected Producer Price Index data, increasing concerns about delayed Federal Reserve easing.

  • Major U.S. indexes are also down more than 0.5%, pressuring risk-sensitive biotechnology and growth shares.
  • The company has investor meetings scheduled at Citi’s Biopharma Back to School Conference on September 10; no new company-specific announcement was identified.